728 related articles for article (PubMed ID: 23023561)
1. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
2. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
[TBL] [Abstract][Full Text] [Related]
3. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.
Rao S; Lyons LS; Fahrenholtz CD; Wu F; Farooq A; Balkan W; Burnstein KL
Oncogene; 2012 Feb; 31(6):716-27. PubMed ID: 21765461
[TBL] [Abstract][Full Text] [Related]
4. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons LS; Rao S; Balkan W; Faysal J; Maiorino CA; Burnstein KL
Mol Endocrinol; 2008 Mar; 22(3):597-608. PubMed ID: 18079321
[TBL] [Abstract][Full Text] [Related]
5. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
6. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
[TBL] [Abstract][Full Text] [Related]
7. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
8. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
9. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
[TBL] [Abstract][Full Text] [Related]
10. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
[TBL] [Abstract][Full Text] [Related]
11. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
12. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.
Sun F; Chen HG; Li W; Yang X; Wang X; Jiang R; Guo Z; Chen H; Huang J; Borowsky AD; Qiu Y
J Biol Chem; 2014 Jan; 289(3):1529-39. PubMed ID: 24297183
[TBL] [Abstract][Full Text] [Related]
15. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.
Wu F; Peacock SO; Rao S; Lemmon SK; Burnstein KL
J Biol Chem; 2013 Feb; 288(8):5463-74. PubMed ID: 23281476
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR
PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732
[TBL] [Abstract][Full Text] [Related]
17. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun S; Sprenger CC; Vessella RL; Haugk K; Soriano K; Mostaghel EA; Page ST; Coleman IM; Nguyen HM; Sun H; Nelson PS; Plymate SR
J Clin Invest; 2010 Aug; 120(8):2715-30. PubMed ID: 20644256
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
19. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
[TBL] [Abstract][Full Text] [Related]
20. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
